Date	Headline
Dec 21, 2020	9 Meters Biopharma Announces Agreement with the European Biomedical Research Institute of Salerno (EBRIS) to Continue Evaluation of Larazotide for COVID-19 Respiratory Complications
Dec 15, 2020	9 Meters Biopharma, Inc. Announces Closing of Offering of Common Stock
Dec 11, 2020	9 Meters Biopharma, Inc. Prices Public Offering of Common Stock
Dec 10, 2020	9 Meters Biopharma, Inc. Announces Proposed Public Offering of Common Stock
Dec 9, 2020	9 Meters Biopharma, Inc. Receives Orphan Drug Designation for NM-003, a Proprietary Long-Acting GLP-2, for Prevention of Acute Graft Versus Host Disease (aGvHD)
Dec 7, 2020	9 Meters Biopharma, Inc. Announces Positive Topline Data for NM-002, a Proprietary Long-Acting GLP-1, in Phase 1b/2a Trial for Short Bowel Syndrome
Nov 16, 2020	9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model
Nov 9, 2020	9 Meters Biopharma, Inc. Provides Business Update and Announces Third Quarter 2020 Results
Nov 2, 2020	9 Meters Biopharma, Inc. to Participate in the Following November Virtual Investor Conferences
Sep 8, 2020	9 Meters Biopharma, Inc. to Participate in September Investor Conferences